@article{4ff0cbef3e744d098f4e5183d38e4374,
title = "Reply: Does Repeat Revascularization Introduce Bias for Reducing Mortality in the Antiplatelet Therapy Group?",
author = "\{SYNTAX Extended Survival Investigators\} and Hideyuki Kawashima and Serruys, \{Patrick W.\} and Rutao Wang and Mattia Lunardi and Yoshinobu Onuma",
note = "Funding Information: The SYNTAX Extended Survival study was supported by the German Foundation of Heart Research (Frankfurt am Main, Germany). The SYNTAX trial, during 0- to 5-year follow-up, was funded by Boston Scientific Corporation, Marlborough, Massachusetts, USA. Both sponsors had no role in the study design, data collection, data analyses and interpretation of the study data, nor were they involved in the decision to publish the final manuscript. The principal investigators and authors had complete scientific freedom. Dr Serruys has received personal fees from SMT, Philips/Volcano, Xeltis, Novartis, and Merillife. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",
year = "2021",
month = nov,
day = "16",
doi = "10.1016/j.jacc.2021.09.012",
language = "English",
volume = "78",
pages = "e173--e174",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "20",
}
SDG 3 Good Health and Well-being